Análisis de la acción Alpha Teknova Inc (TKNO)TKNOAlpha Teknova Inc

Alpha Teknova, Inc. is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. The Company offers three primary product types: pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It offers a range of standard and specialty pre-poured media plates for a variety of applications including bacteria, fungi, and nematode growth. Its two primary product categories include Lab Essentials and Clinical Solutions. Its core Lab Essentials products consist of commonly used catalog solutions and customer-specified formulations. Its Clinical Solutions products are custom products used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Alpha Teknova Inc is a good buy right now due to its recent significant revenue growth of 18% in Q2 2026, reaching over $12 million, and a current price of $7.08, which is below the analyst price target of $9. The company has shown improving fundamentals, including a gross margin of 37.73% in Q2 2026, indicating strong operational efficiency. However, the main risk is the negative net income, which was -3.17 million USD in Q2 2026, highlighting ongoing financial challenges that investors should monitor.